SLS · SELLAS Life Sciences Group, Inc.
$13.21
-2.00 (-13.15%)
At close · Aug 28
Going-concern doubt
— cleared Aug 11, 2026
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Codification ("ASC") 205-40, Presentation of Financial Statements - Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company expects its cash and cash equivalents will be sufficient to fund its current planned operations for at least the next twelve months from the date of issuance of these consolidated financial statements”View the 10-Q filed Aug 11, 2026
Market Cap
$2.77B
Shares
201.95M
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-05-27 | TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA | Event |
| 2026-04-17 | American Association for Cancer Research (AACR) 2026 Annual Meeting Poster | Shareholder meeting |
Key facts
CIK
1390478
CUSIP
81642T209
13F (30d)
164 filings
162 filers
Visit website
Investor relations